Paul Workman

Research interests

Publications

• Challenges to curing primary brain tumours

  Nature Reviews Clinical Oncology · 2019 · https://doi.org/10.1038/s41571-019-0177-5

• Patient-derived organoids model treatment response of metastatic gastrointestinal cancers

  Science · 2018 · https://doi.org/10.1126/science.aao2774

• Inhibitors of cyclin-dependent kinases as cancer therapeutics

  Pharmacology & Therapeutics · 2017 · 10.1016/j.pharmthera.2017.02.008

• Imaging biomarker roadmap for cancer studies

  Nature Reviews Clinical Oncology · 2016 · 10.1038/nrclinonc.2016.162

• First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

  Clinical Cancer Research · 2014 · 10.1158/1078-0432.ccr-14-0947

• Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN

  Cancer Discovery · 2013 · 10.1158/2159-8290.cd-12-0426

• Combinatorial drug therapy for cancer in the post-genomic era

  Nature Biotechnology · 2012 · 10.1038/nbt.2284

• Discovery of small molecule cancer drugs: Successes, challenges and opportunities

  Molecular Oncology · 2012 · 10.1016/j.molonc.2012.02.004

• Guidelines for the welfare and use of animals in cancer research

  British Journal of Cancer · 2010 · 10.1038/sj.bjc.6605642

• The Identification of 2-(1 H -Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2- d ]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer

  Journal of Medicinal Chemistry · 2008 · 10.1021/jm800295d

• NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis

  Cancer Research · 2008 · 10.1158/0008-5472.can-07-5256

• The Hsp90 molecular chaperone: an open and shut case for treatment

  Biochemical Journal · 2008 · 10.1042/bj20071640

• Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises

  Current Opinion in Pharmacology · 2008 · 10.1016/j.coph.2008.08.004

• Inhibitors of the heat shock response: Biology and pharmacology

  FEBS Letters · 2007 · 10.1016/j.febslet.2007.05.040

• Drugging the Cancer Chaperone HSP90

  Annals of the New York Academy of Sciences · 2007 · 10.1196/annals.1391.012

• 4,5-Diarylisoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer

  Journal of Medicinal Chemistry · 2007 · 10.1021/jm701018h

• Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases

  Cancer Research · 2007 · 10.1158/0008-5472.can-06-4615

• New approaches to molecular cancer therapeutics

  Nature Chemical Biology · 2006 · 10.1038/nchembio840

• Inhibitors of the HSP90 Molecular Chaperone: Current Status

  Advances in cancer research · 2006 · 10.1016/s0065-230x(06)95009-x

• The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations

  British Journal of Cancer · 2005 · 10.1038/sj.bjc.6602550

• Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced Malignancies

  Journal of Clinical Oncology · 2005 · 10.1200/jco.2005.00.612

• HSP90 as a new therapeutic target for cancer therapy: the story unfolds

  Expert Opinion on Biological Therapy · 2002 · 10.1517/14712598.2.1.3

• Activation of the ATPase Activity of Hsp90 by the Stress-Regulated Cochaperone Aha1

  Molecular Cell · 2002 · 10.1016/s1097-2765(02)00785-2

• Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis.

  PubMed · 2001

• DT-Diaphorase Expression and Tumor Cell Sensitivity to 17-Allylamino,17-demethoxygeldanamycin, an Inhibitor of Heat Shock Protein 90

  JNCI Journal of the National Cancer Institute · 1999 · 10.1093/jnci/91.22.1940

• UKCCCR guidelines for the welfare of animals in experimental neoplasia

  Laboratory Animals · 1988 · 10.1258/002367788780746467

Current projects

No projects listed.